about
3D vs 2D laparoscopic radical prostatectomy in organ-confined prostate cancer: comparison of operative data and pentafecta rates: a single cohort study.Ultrasound of the prostate.Single positive core prostate cancer in a 12-core transrectal biopsy scheme: clinicopathological implications compared with multifocal counterpart.Evaluation of degarelix in the management of prostate cancer.The basis for monitoring strategies in clinical guidelines: a case study of prostate-specific antigen for monitoring in prostate cancer.Urinary adverse effects of pelvic radiotherapy.Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis.Protocol for the ProCare Trial: a phase II randomised controlled trial of shared care for follow-up of men with prostate cancer.High-intensity focused ultrasound: where are we and where to from here?Novel, potent anti-androgens of therapeutic potential: recent advances and promising developments.Complications of prostate biopsy.Preliminary safety and efficacy results with robotic high-intensity focused ultrasound : A single center Indian experienceA comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.Circulating and disseminated tumor cells in the management of advanced prostate cancer.Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?Results of radical prostatectomy in newly diagnosed prostate cancer: long-term survival rates in locally advanced and high-risk cancersInverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade.Influence of obesity on tumour volume in patients with prostate cancer.When should we expect no residual tumor (pT0) once we submit incidental T1a-b prostate cancers to radical prostatectomy?Treatment of prostate cancer with intensity modulated radiation therapy (IMRT).
P2860
Q30936063-4CC3CCA0-6CB3-4797-BB59-2C29D8834CC3Q33741371-C259D246-5515-4D3B-BF06-9C76102467FCQ34238989-266EDABC-9C7D-4D79-80E6-128F15A532AEQ34417797-A219D2F4-ECEB-4FA2-999E-84AC2DE40765Q35739865-D8019BBD-2DC3-4CB0-9F74-2BA51500DC29Q36450629-14E47603-6F3A-413D-9E11-9F52AD9C77BAQ37554029-01DBF530-C9D2-4AC1-9003-3AE9289C6FEDQ37628507-5E4D8D52-382A-45B4-9A62-CE2AB02C52A0Q37656210-B8A19735-3F86-4201-83AA-6BC9389B1A86Q37855836-B95D17AD-39EC-4F3B-92D6-AC90C061270EQ38123203-0D0821E1-1AC7-4AD4-AB11-A2DBE065821DQ38710610-F99B095E-F251-43D3-8734-593954162BB7Q39999913-80F00B73-E932-4B69-96B8-9327348B8984Q42159492-0CFA801D-FCEB-4729-91A8-51992647AF95Q42243425-51715C2F-CDD4-4B36-A8E7-7F8B8DD100FFQ42567335-9A1AEEAF-E5B6-45EE-8BC0-3A330879534DQ45047233-3AD10544-3EF2-4AA9-A993-32C0BC7812CFQ46770186-D758D24A-E583-464A-AC31-A52216F96894Q51617842-EDEDD880-6D01-4BFE-A3CE-CCB83E5EA5FBQ53531406-AD6DE381-B16F-4883-AFAF-A017BBB0717B
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
[EAU guidelines on prostate cancer].
@ast
[EAU guidelines on prostate cancer].
@en
[EAU guidelines on prostate cancer].
@nl
type
label
[EAU guidelines on prostate cancer].
@ast
[EAU guidelines on prostate cancer].
@en
[EAU guidelines on prostate cancer].
@nl
prefLabel
[EAU guidelines on prostate cancer].
@ast
[EAU guidelines on prostate cancer].
@en
[EAU guidelines on prostate cancer].
@nl
P2093
P1476
[EAU guidelines on prostate cancer]
@en
P2093
Axel Heidenreich
European Association of Urology
Filliberto Zattoni
Hans Peter Schmid
Michel Bolla
Vsevolod B Matveev
P304
P356
10.1016/S0210-4806(09)74110-5
P577
2009-02-01T00:00:00Z